Knowledge Base for Investigators

Searching for patient related article? Navigate to the 
Knowledge Base for Patients

RegenMed Master Services Agreement

See this document in PDF view mode

August 29, 2022


TABLE OF CONTENTS

  1. Parties
    1. The Company
    2. Client
  2. Purpose of Agreement
  3. Documents Incorporated by Reference
  4. Company Responsibilities
    1. Delivery of Products and Services
    2. inCytes™ Service Level Commitment
  5. Payment of Products and Services Charges
  6. Data Ownership
    1. Aggregated Data
    2. Company Not Responsible For Third Party Claims
  7. Circle Liabilities
  8. Communications
  9. Miscellaneous
    1. Final Agreement
    2. Conflict
    3. Governing Law
    4. Counterparts
    5. Termination

1. Parties

1.1. The Company

1.2. Client

[Full name and address].

2. Purpose of Agreement

This Agreement specifies the general terms and conditions applicable to the delivery by the Company to the Client of one or more Products and Services. All Statements of Work (“SOW”) between the Company and the Client shall be governed by this Agreement.

3. Documents Incorporated by Reference

The following documents are incorporated into and deemed a part of this Agreement.

a. Legal. See here.

b. inCytes™ License Agreement. See here.

c. Privacy Policy. See here.

d. Products and Services Charges and Payment Policies. See here.

4. Company Responsibilities

4.1. Delivery of Products and Services

In consideration of payment by the Client of all applicable Products and Services Charges as specified in an SOW, the Company shall deliver to the Client, and/or other Persons specified by the Client, the Products and Services specified in such SOW or an Authorized Amendment.

4.2. inCytes™ Service Level Commitment

The inCytes™ Platform shall be accessible for at least 97% each month. The Company shall provide at least five business days’ notice of any planned maintenance downtime. The Client shall not be responsible for payment of any Subscription Months in calendar months in which this commitment is not met by the Company.

5. Payment of Products and Services Charges

The Client shall pay all Product and Service Charges incurred as a result of this Agreement and any SOW or Authorized Amendment in accordance with the Payment Terms.

6. Data Ownership

6.1. Aggregated Data

Aggregated Data generated through any Circle funded hereunder shall be owned by the Company, the Client and any other Person as agreed by and among all of them in a separate writing (“Aggregated Data Ownership Agreement”), provided that:

a. The Company shall retain an ownership interest in all such Aggregated Data unless and to the extent it expressly agrees in writing to the contrary.

b. In the absence of an Aggregated Data Ownership Agreement providing to the contrary, no Aggregated Data shall be licensed, sold or otherwise monetized by the Company, the Client or any Investigator.

c. Notwithstanding anything in this Agreement to the contrary, any of the Client and the Company may utilize Aggregated Data for any non-profit purpose.

6.2. Company Not Responsible for Third Party Claims

The Company shall not be responsible for any conflicts arising between the Client and any Investigator or other Person regarding ownership of or rights to data (whether Personal Data or other). Client indemnifies the Company with respect to any costs or expenses, including legal fees, incurred by the Company as a result of any claims brought against the Company by such Investigator or other third party based on such alleged rights to such data, unless and only to the extent such claims relate to breaches by the Company of its obligations hereunder.

7. Circle Liabilities

The Company shall have no responsibility or liability for any adverse events, patient claims or matters arising from the use by the Client or Investigators arising from the design or execution of a Circle. Client shall indemnify and hold harmless the Company for all such liabilities and related costs and expenses, including attorney’s fees.

8. Communications

All communications intended to have legal effect shall be sent and expressly accepted in writing by an Authorized Representative of each party, as follows:

For the Company: to ntierney@rgnmed.com.

For the Client: ___________________.

9. Miscellaneous

9.1. Final Agreement

This Agreement shall be the final agreement between the Parties concerning its subject matter, shall supersede any other writings or understandings, and may not be assigned or amended without the express written agreement of both Parties.

9.2. Conflict

In the event of any conflict between the inCytes™ License Agreement and this Agreement, the applicable provision(s) of the inCytes™ License Agreement shall prevail.

9.3. Governing Law

This Agreement shall be governed by the laws of the State of Delaware, U.S.A., and both parties submit to the courts of that State for the purpose of resolving any disputes arising hereunder.

9.4. Counterparts

This Agreement may be signed in counterparts. A copy of this Agreement or of an SOW sent to the address indicated in paragraph 8 above, and acknowledged by the receiving party, shall be considered the equivalent of the original of such document.

Date:

Accepted and agreed:

On behalf of the Company On behalf of the Client
__________________________ __________________________
Name: Name:
Title: Title:

Search keywords:

Haven't found a solution?

CONTACT US